Bio X Cell bispecific antibodies

Bispecific antibodies are an advanced class of biologics engineered to recognise and bind two distinct antigens or epitopes simultaneously. By bridging cellular interactions or co‑targeting molecular pathways, Bio X Cell's in vivo-ready bispecifics offer a powerful strategy for immune cell redirection, dual‑pathway blockade, payload delivery, and enhanced selectivity.

In drug discovery and translational research, bispecific antibodies are increasingly used to:

• Redirect T cells or NK cells for targeted cytotoxicity
• Engage multiple immune checkpoints
• Block redundant or compensatory signalling pathways
• Improve tumour specificity and reduce off‑target effects
• Explore novel immune‑therapeutic mechanisms in oncology, autoimmunity, and infectious disease

Bio X Cell’s curated bispecific antibody portfolio offers multiple formats and is designed to support the rapid development and validation of innovative therapeutic concepts, offering high‑purity, in vivo-grade reagents backed by the quality standards researchers expect.

• Anti-mouse bispecific antibodies: purpose-built, in vivo-ready bispecific reagents optimised for murine studies, closely modeled on clinical formats to support reliable mechanism‑of‑action and efficacy insights.
• Anti-human bispecific biosimilars: high-fidelity biosimilar bispecifics engineered to reflect therapeutic antibodies, enabling precise benchmarking and translational validation from discovery through development.
• Custom bispecific engineering: tailored bispecific antibody design backed by expert scientific guidance and scalable manufacturing solutions, accelerating advancement of bispecific pipelines.

Bio X Cell’s bispecific solutions

• Mouse-specific bispecific antibodies provide researchers the tools they need for mouse models, without having to invest in expensive humanised mice.
• Biosimilars of clinical bispecifics enable research comparisons with therapeutic formats
• Bispecifics are dual-target validated, high purity and in vivo ready, allowing researchers to run studies immediately without waiting for custom constructs
• Consistent, low endotoxin, reproducible bispecifics reduce experimental variability, helping researchers generate cleaner data faster, lowering risk and accelerating go/no-go decisions
• Researchers can use ready to ship bispecifics or choose custom services.

*Engineered mouse bispecifics designed to dually target murine antigens corresponding to the therapeutic targets listed above.

The first commercially available trispecific antibody

Bio X Cell’s CPB536 introduces a trispecific approach to studying combinatorial checkpoint biology, enabling simultaneous targeting of PD-L1, TIGIT, and LAG-3 within a single molecule. This 2+2 tetravalent format supports the coordinated blockade of three complementary inhibitory pathways while bridging tumour or antigen-presenting cells with T cells. By allowing investigation of T-cell exhaustion and multi-checkpoint inhibition in one system, CPB536 expands the tools available for modelling more complex and physiologically relevant anti-tumour immune responses in vivo.

Material for download

Bio X Cell bispecific antibodies brochure

Bio X Cell bispecific antibodies product flyer